Aclaris Therapeutics ACRS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's operating cash flow?
- Aclaris Therapeutics (ACRS) reported operating cash flow of -$18.15M in Q1 2026.
- How has Aclaris Therapeutics's operating cash flow changed year-over-year?
- Aclaris Therapeutics's operating cash flow decreased by 39.0% year-over-year, from -$13.06M to -$18.15M.
- What is the long-term trend for Aclaris Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Aclaris Therapeutics's operating cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$52.13M to -$47.11M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.